It was a short trial. Only 2 years.
On a positive note, APOE4 carriers with the highest ratio of DHA to AA (arachodonic acid) did show less cognitive decline in the trial, relative to carriers with the lowest ratio.
See this previous post, describing the trial in more detail: ↪ PREVENT-E4: 2 g/day DHA did not slow cognitive decline in 365 at-risk older adults.
Another positive finding was that cerebral spinal fluid (CSF) levels of DHA were just as high in APOE4 carriers as in non-carriers, dispelling the myth that high-dose DHA (2g) does not cross the blood brain barrier very well in APOE4’s. This trial proved definitively that it does.
#dhaHD #fishoilHD #omega3HD #prevente4HD #alzheimersHD #dementiaHD #apoe4HD #hippocampusHD #arachadonicacidHD


